Innoviva Market Cap 2010-2024 | INVA

Innoviva market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Innoviva market cap as of December 20, 2024 is $1.12B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.122B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $719.145B 74.49
Novo Nordisk (NVO) Denmark $464.190B 33.48
Johnson & Johnson (JNJ) United States $345.687B 14.02
AbbVie (ABBV) United States $303.100B 15.95
Merck (MRK) United States $251.749B 16.73
AstraZeneca (AZN) United Kingdom $199.805B 17.00
Novartis AG (NVS) Switzerland $197.798B 13.15
Pfizer (PFE) United States $146.038B 9.99
Sanofi (SNY) $120.547B 10.92